Recruiting NCT05349240
C2 Esophageal Squamous Epithelium Dysplasia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: C2 CryoBalloonTM Ablation System..
- Who it may be relevant to
- Registry conditions: Esophageal Squamous Epithelium Dysplasia. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Prospective, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of C2 CryoBalloonTM Ablation System in Patients With Esophageal Squamous Epithelium Dysplasia
Overview
This study will evaluate the efficacy and safety of C2 CryoBalloonTM Ablation System for the cryoablation of dysplastic squamous tissue in patients with moderate to severe esophageal squamous epithelium dysplasia.
Interventions
- Device C2 CryoBalloonTM Ablation System.
Cryoablation is used to ablate the tissue under the cryogenic condition. The device is mainly used to destroy the unhealthy tissues.
Primary outcome measures
- Percentage of subjects who have complete remission of all the moderate to severe dysplasia in initial treatment area [Time frame: 12 Month]
Secondary outcome measures (2)
- 1) Percentage of subjects who have complete remission of all the moderate to severe dysplasia in initial by one time of treatment [Time frame: 12 Month]
- 2) Percentage of patients with complete remission of all the moderate to severe dysplasia in initial treatment area [Time frame: 12 Month]
Eligibility criteria
Inclusion criteria
- Male or female of 18 to 80 years old (including 18 and 80 years old).
- At least one unstained lesion (USL) in the esophagus upon high resolution upper gastrointestinal endoscopy with Lugol's staining. Flat (Paris type 0-IIb) USL, with the total area of one or more USLs having a maximum longitudinal size of 6 cm and covering a maximum of one-half of the esophageal circumference.
- Patients with one or more biopsy confirmed esophageal squamous epithelium dysplasia areas within 6 months prior to enrollment, and the pathological diagnosis is moderate to severe esophageal squamous epithelium dysplasia.
- No potential of lymph node metastasis by preoperative comprehensive evaluation.
Exclusion criteria
Inclusion criteria
- Male or female of 18 to 80 years old (including 18 and 80 years old).
- At least one unstained lesion (USL) in the esophagus upon high resolution upper gastrointestinal endoscopy with Lugol's staining. Flat (Paris type 0-IIb) USL, with the total area of one or more USLs having a maximum longitudinal size of 6 cm and covering a maximum of one-half of the esophageal circumference.
- Patients with one or more biopsy confirmed esophageal squamous epithelium dysplasia areas within 6 months prior to enrollment, and the pathological diagnosis is moderate to severe esophageal squamous epithelium dysplasia.
- No potential of lymph node metastasis by preoperative comprehensive evaluation.
- The patients are self volunteered to participate in the trial and will sign an informed consent form prior to enroll.
Exclusion criteria
- Females who are pregnant, lactating or plan to get pregnant during the study.
- Known hypersensitivity to iodine.
- Lesions within the target area such as: obvious ulcer; varices at risk of bleeding; active inflammation due to esophageal reflux into the treatment area; lesions view being not flat, or containing unfavourable unstained lesions (USLs) outside the designated treatment areas.
- Esophageal stenosis preventing the passage of the endoscope to the treatment area. Esophageal stenosis or stricture preventing advancement of a therapeutic endoscope within 4 cm of the treatment area.
- Having previously received Heller surgery: any previous ablative esophageal surgery (photodynamic therapy, multipolar electrical coagulation, argon plasma coagulation, laser treatment) or any previous esophageal surgery except for anti-reflux surgery.
- Suffering from any cancer in the past 5 years.
- Severe bleeding potential; patients on anti-coagulative therapy or stopping using anti-coagulative drugs for less than 7 days before enrollment or with impaired coagulation.
9\) Patients with unstable vital signs 10) Anti-human immunodeficiency virus (HIV) antibody positive, both syphilis serology Treponema pallidum-specific antibody test and rapid plasma reagin positive.
\-
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 4 centers
- Cancer Hospital Chinese Academy of Medical Sciences — Beijing
- The First Bethune Hospital of Jilin University — Changchun
- Changzhi People's Hospital — Changzhi
- The Second Hospital of Hebei Medical University — Shijiazhuang
Identifiers
NCT: NCT05349240 · CBAS_DIII_19001